{"entity":{"id":"apmonia-therapeutics","kind":"company","name":"Apmonia Therapeutics","aka":[],"tldr":"Apmonia Therapeutics makes small ring-shaped peptides aimed at the tissue around tumours. Its first medicine blocks a signal that helps tumours suppress the immune system, and is starting its first trial in people with advanced solid tumours.","summary":"Apmonia Therapeutics, headquartered in Reims, France, was founded in 2019 as a spin-off of CNRS and the University of Reims (UMR 7369 MEDyC), according to the company, and set up an R&D subsidiary in Liege, Belgium in August 2025. It develops peptide therapies against the extracellular matrix of the tumour microenvironment. Its lead, TAX2 (programme AP-01), is a cyclic peptide that targets thrombospondin-1 (TSP-1), designed to disrupt the TSP-1 and CD47 interaction while sparing the CD47 and SIRP-alpha pathway, with the aim of avoiding the blood toxicities of systemic CD47 blockade. A first-in-human phase 1/2a dose-escalation trial (NCT07688148) of weekly TAX2 in relapsed or refractory advanced solid tumours is planned at sites in Brussels, Ghent, Lyon and Villejuif. In July 2024 the company announced it would receive a 2.5 million euro grant and a 7 million euro equity investment as a European Innovation Council Accelerator laureate, and in February 2026 it secured 10 million euros from Capital Grand-Est, FINOVAM Gestion, the Fournier-Majoie Foundation, Angels Sante, new private investors and Capital Cell. Its first registered cancer trial, NCT07688148, was posted on ClinicalTrials.gov in July 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://apmonia-therapeutics.com/"},{"label":"About Apmonia","url":"https://apmonia-therapeutics.com/index.php/about-us/"},{"label":"EUR 10 million financing release, February 2026","url":"https://apmonia-therapeutics.com/index.php/2026/02/03/apmonia-therapeutics-secures-e10-million-to-advance-first-in-human-development-of-first-in-class-cancer-therapy-tax2/"},{"label":"ClinicalTrials.gov: first-in-human trial of TAX2 (NCT07688148)","url":"https://clinicaltrials.gov/study/NCT07688148"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cd47-blockade"],"targets":["cd47"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and spin-off origin from the company's About page, read on 29 October 2026.","The thrombospondin-1 target has no target record, so only CD47 is linked; TAX2 does not block CD47 itself but the TSP-1 binding to it.","The trial was not yet recruiting when read."],"hq":"Reims","country":"FR","companyType":"biotech","website":"https://apmonia-therapeutics.com/","founded":2019,"stage":"startup","investors":[],"funding":[{"round":"EIC Accelerator grant and equity","year":2024,"source":"https://apmonia-therapeutics.com/index.php/2024/07/16/apmonia-therapeutics-to-receive-e2-5m-grant-and-e7m-equity-investment-from-the-european-innovation-council-eic-as-a-laureate-of-the-eic-accelerator-program/","note":"EUR 2.5 million grant and EUR 7 million equity from the European Innovation Council; USD amount not stated; the release body was not read beyond its headline and summary"},{"round":"Financing","year":2026,"source":"https://apmonia-therapeutics.com/index.php/2026/02/03/apmonia-therapeutics-secures-e10-million-to-advance-first-in-human-development-of-first-in-class-cancer-therapy-tax2/","note":"EUR 10 million from Capital Grand-Est, FINOVAM Gestion, Fournier-Majoie Foundation, Angels Sante, new private investors and Capital Cell; USD amount not stated"}]},"route":"/companies/apmonia-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}]}}